Literature DB >> 12108861

Prospective population-based study on the survival of patients with lung cancer.

R Mäkitaro1, P Pääkko, E Huhti, R Bloigu, V L Kinnula.   

Abstract

The purpose of this study was to evaluate the change, over 20 yrs, in the survival of lung cancer patients in a population-based study. Information on all patients with lung cancer in a defined geographical area during 1990-1992 (n=602) was prospectively gathered. The survival of these patients was assessed and also compared with the results of a similar study in the same area during the years 1968-1971 (n=446). The 5-yr survival had improved during 20 yrs from 4% to 12%. The 5-yr survival of the patients with squamous cell carcinoma had increased from 6% to 16%, and adenocarcinoma from 4% to 19%, whereas the survival of small cell carcinoma had remained the same (2% and 3%, respectively). Even though the recent patients were older than those of the earlier series the proportion of surgically treated patients had remained the same (16% and 20%), but the 5-yr survival of patients who had been operated on had increased significantly from 23% to 48%. The differences in survival in the second cohort (1990-1992) between histological types (Chi-squared logrank=59.2), tumour, node, metastasis stages (Chi-squared logrank=199.6), symptomatic stages (Chi-squared logrank=120, p<0.001) and treatment (Chi-squared logrank=277) were significant. Based on this study the independent prognostic factors for better survival of lung cancer patients are tumour, node, metastasis stages I and II, surgical treatment and Feinstein's symptomatic stages I and II.

Entities:  

Mesh:

Year:  2002        PMID: 12108861     DOI: 10.1183/09031936.02.00048302

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  8 in total

1.  Clinical significance of preoperative carcinoembryonic antigen level in patients with clinical stage IA non-small cell lung cancer.

Authors:  Ryo Maeda; Takashi Suda; Ayumi Hachimaru; Daisuke Tochii; Sachiko Tochii; Yasushi Takagi
Journal:  J Thorac Dis       Date:  2017-01       Impact factor: 2.895

2.  Factors affecting 30-month survival in lung cancer patients.

Authors:  P A Mahesh; S Archana; B S Jayaraj; Shekar Patil; S K Chaya; H P Shashidhar; B S Sunitha; A K Prabhakar
Journal:  Indian J Med Res       Date:  2012-10       Impact factor: 2.375

Review 3.  Maintenance and consolidation therapy in patients with unresectable stage III/IV non-small cell lung cancer.

Authors:  Nicholas Thatcher; Jim Heighway
Journal:  Oncologist       Date:  2010-10-07

4.  Diagnostic efficacy of broncho-alveolar lavage carcino-embronic antigen in carcinoma of lung.

Authors:  Sudarsan Pothal; Kamlesh P Patil; Rekha Manjhi; Pravati Dutta
Journal:  J Family Med Prim Care       Date:  2019-05

5.  Downregulation of miR-506-3p Facilitates EGFR-TKI Resistance through Induction of Sonic Hedgehog Signaling in Non-Small-Cell Lung Cancer Cell Lines.

Authors:  Inamul Haque; Hameem I Kawsar; Hannah Motes; Mukut Sharma; Snigdha Banerjee; Sushanta K Banerjee; Andrew K Godwin; Chao H Huang
Journal:  Int J Mol Sci       Date:  2020-12-06       Impact factor: 5.923

6.  Demographic differentials of lung cancer survival in Bangladeshi patients.

Authors:  Muhammad Rafiqul Islam; A T M Kamrul Hasan; Nazrina Khatun; Ishrat Nur Ridi; Md Mamun Or Rasheed; Syed Mohammad Ariful Islam; Md Nazmul Karim
Journal:  PLoS One       Date:  2021-12-10       Impact factor: 3.240

7.  Is investigation of patients with haemoptysis and normal chest radiograph justified?

Authors:  M Thirumaran; R Sundar; I M Sutcliffe; D C Currie
Journal:  Thorax       Date:  2009-05-19       Impact factor: 9.139

8.  Usefulness of serum carcinoembryonic antigen (CEA) in evaluating response to chemotherapy in patients with advanced non small-cell lung cancer: a prospective cohort study.

Authors:  Oscar Arrieta; Cynthia Villarreal-Garza; Luis Martínez-Barrera; Marcelino Morales; Yuzmiren Dorantes-Gallareta; Omar Peña-Curiel; Susana Contreras-Reyes; Eleazar Omar Macedo-Pérez; Jorge Alatorre-Alexander
Journal:  BMC Cancer       Date:  2013-05-22       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.